Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 18/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275523 | 1.00 | NAMPT (0.71) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL31596947 | 0.99 | NAMPT (0.70) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL31596978 | 0.94 | NAMPT (0.66) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL22126980 | 0.90 | NAMPT (0.80) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL22126982 | 0.90 | NAMPT (0.80) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL31606436 | 0.89 | NAMPT (0.68) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL31606428 | 0.89 | NAMPT (0.67) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL20095305 | 0.89 | NAMPT (0.79) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL20095600 | 0.85 | NAMPT (0.82) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL30275527 | 0.84 | NAMPT (0.82) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | NAMPT 1/4885CYP3A4 4804/4885CYP2C9 4269/4885 |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SSB, UACA, CDA | NAMPT 801/4885CYP3A4 4396/4885CYP2C9 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.